Ligand Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $37.9K
- Price
- $0.0019
- % Change (Daily % change from the live per-ticker quote feed.)
- +18.75%
- Volume
- 10.0K
About
Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its comprehensive product line features treatments such as evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was established in 1987 by Ronald M. Evans and is headquartered in Jupiter, Florida.
Quick stats
Shares outstanding19.9M
Computed float18.9M
Float / shares94.7%
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000886163
Websitehttps://www.ligand.com
AI Summary
AI-generated1/38
majorbullishearnings
Ligand Reports Second Quarter 2026 Financial Results
Ligand reported Q2 revenue of $63.7 million, up 34% year-over-year, driven by a 32% increase in royalty revenue to $48.0 million. Adjusted EPS reached $2.37, reflecting strong year-over-year growth supported by gains from its royalty portfolio and strategic investments.
The company closed the XOMA Royalty acquisition, adding over 120 assets, and completed a $700 million 0% convertible debt financing. These moves significantly expand Ligand's portfolio and strengthen its capital position with $1.36 billion in cash and equivalents.
Management reaffirmed full-year revenue guidance of $270 million to $310 million and raised the low end of its Adjusted EPS guidance range to $9.00 to $9.50. The increase is attributed to cost synergies from the XOMA deal and incremental interest income from the new notes.